Microbiome CNS upstart launches with $19.15M Series A

The Series A financing was led by Longwood Fund and Domain Associates.

Longwood Fund and Domain Associates have led a $19.15 million funding round for newco Axial Biotherapeutics with the aim of creating new treatments for an array of CNS disorders by harnessing the gut microbiome.

It starts life with exclusive, global rights to a new class of CNS biotherapeutics from the Mazmanian Laboratory at Caltech.

Axial said its focus will be to “translate these discoveries into a unique class of microbial-targeted biotherapeutics that could become breakthrough therapies for a variety of neurological diseases and disorders, including ASD, Parkinson’s and Alzheimer’s disease.”

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Its fundamental approach will come from leveraging the work of its scientific founder, Professor Sarkis Mazmanian, which uses the gut microbiome to help treat diseases and disorders of the central nervous system, specifically to build a microbiome discovery platform targeting the gut-brain axis.

The Series A financing was led by Longwood Fund and Domain Associates, with Kairos Ventures, Heritage Medical Systems and a group of “high net worth individuals” based in Southern California also taking part.

Venture partner at Longwood Fund David Donabedian, and former GSK and AbbVie vet, becomes the biotech’s new CEO and board director.

“I look forward to developing this world class science into treatments which have the potential to help patients where limited treatment options are available,” said Donabedian.

“There is mounting evidence that the gut microbiome is implicated in brain development and neurological health and we believe we are at the forefront of generating new avenues for microbiome-targeted therapeutic interventions in multiple neurological diseases and disorders.” 

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.